$CGEM has received 9 mentions from 2 distinct FinTwit voices over the past 12 months, with the first mention appearing on July 3, 2025. The biotech-focused discussion has been dominated by @jacobplieth, who accounts for 8 of the 9 mentions, while @adamfeuerstein contributed 1 mention. The most recent activity occurred on May 29, 2026, when @jacobplieth posted twice regarding clinical data from the WU-Kong28 trial presented at ASCO26, discussing Dizal Zegfrovy results in first-line exon20 NSCLC.

The conversation around $CGEM has centered on clinical trial outcomes and competitive dynamics within the oncology space. @jacobplieth's recent posts reference Dizal data appearing in NEJM and note that crossover affected overall survival benefit in the trial. Earlier mention by @adamfeuerstein in May 2026 touched on competitive positioning, referencing UCB's evaluation of $CGEM alongside their Candid acquisition consideration.